NanoBio Corporation
BlueWillow Biologics is a pioneering biopharmaceutical company focused on developing and commercializing intranasal vaccines and treatments using its patented NanoVax® technology platform. The company aims to transform disease prevention and treatment through innovative vaccine platforms that elicit both mucosal and systemic immunity. Their research spans infectious diseases, including respiratory and sexually transmitted infections, as well as allergic conditions and cancer. With a strong leadership team and ongoing collaborations, BlueWillow is committed to advancing vaccine science to address global health challenges.
Industries
Nr. of Employees
small (1-50)
NanoBio Corporation
Patents
Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
US-12076397-B2
View DetailsPersistent topical antimicrobial compositions and methods of using the same
US-11369578-B2
View Details
Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
US-12076397-B2
View DetailsPersistent topical antimicrobial compositions and methods of using the same
US-11369578-B2
View DetailsProducts
Intranasal anthrax vaccine candidate
Recombinant-protein intranasal vaccine formulated with a nanoemulsion adjuvant; evaluated in preclinical models and early-phase clinical studies for safety and immunogenicity.
Intranasal H5N1 / pandemic influenza vaccine candidate
Nanoemulsion-adjuvanted intranasal vaccine targeting pandemic influenza antigens; advanced in NIH-funded trials with reported broad immune responses and no serious adverse events in Phase 1.
Intranasal SARS-CoV-2 vaccine candidate (collaborative)
Preclinical intranasal vaccine combining stabilized spike antigen concepts with a nanoemulsion adjuvant to induce neutralizing and mucosal IgA responses in animal studies.
Intranasal genital herpes (HSV-2) vaccine candidate
Intranasal vaccine candidates evaluated in animal models for prophylactic and therapeutic effects, including reduction of recurrent lesions and viral shedding.
Intranasal peanut allergy therapeutic vaccine (preclinical)
Intranasal immunotherapy approach combining small amounts of purified peanut protein with a nanoemulsion delivery system to reprogram immune responses and reduce allergic reactions in animal models; advanced with NIH/NIAID contract funding.
Pipeline intranasal vaccines for RSV, pertussis, chlamydia and other indications
Platform-adapted intranasal candidates and preclinical programs targeting respiratory and sexually transmitted infections and selected allergic conditions.
Intranasal anthrax vaccine candidate
Recombinant-protein intranasal vaccine formulated with a nanoemulsion adjuvant; evaluated in preclinical models and early-phase clinical studies for safety and immunogenicity.
Intranasal H5N1 / pandemic influenza vaccine candidate
Nanoemulsion-adjuvanted intranasal vaccine targeting pandemic influenza antigens; advanced in NIH-funded trials with reported broad immune responses and no serious adverse events in Phase 1.
Intranasal SARS-CoV-2 vaccine candidate (collaborative)
Preclinical intranasal vaccine combining stabilized spike antigen concepts with a nanoemulsion adjuvant to induce neutralizing and mucosal IgA responses in animal studies.
Intranasal genital herpes (HSV-2) vaccine candidate
Intranasal vaccine candidates evaluated in animal models for prophylactic and therapeutic effects, including reduction of recurrent lesions and viral shedding.
Intranasal peanut allergy therapeutic vaccine (preclinical)
Intranasal immunotherapy approach combining small amounts of purified peanut protein with a nanoemulsion delivery system to reprogram immune responses and reduce allergic reactions in animal models; advanced with NIH/NIAID contract funding.
Pipeline intranasal vaccines for RSV, pertussis, chlamydia and other indications
Platform-adapted intranasal candidates and preclinical programs targeting respiratory and sexually transmitted infections and selected allergic conditions.
Services
Partnership-based development of vaccine candidates including antigen integration, nanoemulsion formulation and licensing of adjuvant platform technology to external partners.
Execution of preclinical efficacy and challenge studies, GLP/non-GLP toxicology and process development to generate data packages for regulatory submissions.
Management and delivery of contract- and grant-funded vaccine R&D programs supported by federal agencies and competitive awards.
Partnership-based development of vaccine candidates including antigen integration, nanoemulsion formulation and licensing of adjuvant platform technology to external partners.
Execution of preclinical efficacy and challenge studies, GLP/non-GLP toxicology and process development to generate data packages for regulatory submissions.
Management and delivery of contract- and grant-funded vaccine R&D programs supported by federal agencies and competitive awards.
Expertise Areas
- Intranasal vaccine development
- Mucosal immunology and mucosal immunity induction
- Vaccine adjuvant formulation (oil-in-water nanoemulsions)
- Preclinical animal models and challenge studies
Key Technologies
- Oil-in-water nanoemulsion adjuvant
- Intranasal delivery
- Intramuscular delivery
- Mucosal immunity induction
News & Updates
Presentation will demonstrate safety and immunogenicity, provide an update on NIH-funded bird flu trial, and highlight the technology’s potential in pandemic preparedness.
NanoBio presented new data showing the benefits of its nanoemulsion adjuvant in developing an intranasal herpes simplex virus-2 (HSV-2) vaccine, demonstrating protection and immune response in preclinical models.
BlueWillow received a Fast-Track SBIR contract from NIAID to develop an intranasal therapeutic peanut allergy vaccine, aiming to reprogram the immune system to induce long-term suppression of allergic reactions.
Interim results from Phase 1 trial of BW-1010 show safety and immune response, supporting further development.
The company announced FDA clearance to begin clinical trials of its intranasal anthrax vaccine candidate.
Patent protects the use of NanoVax platform for HSV vaccine, supporting development of intranasal herpes vaccines.
Presentation will demonstrate safety and immunogenicity, provide an update on NIH-funded bird flu trial, and highlight the technology’s potential in pandemic preparedness.
NanoBio presented new data showing the benefits of its nanoemulsion adjuvant in developing an intranasal herpes simplex virus-2 (HSV-2) vaccine, demonstrating protection and immune response in preclinical models.
BlueWillow received a Fast-Track SBIR contract from NIAID to develop an intranasal therapeutic peanut allergy vaccine, aiming to reprogram the immune system to induce long-term suppression of allergic reactions.
Interim results from Phase 1 trial of BW-1010 show safety and immune response, supporting further development.
The company announced FDA clearance to begin clinical trials of its intranasal anthrax vaccine candidate.
Patent protects the use of NanoVax platform for HSV vaccine, supporting development of intranasal herpes vaccines.